Type 1 Diabetes: Competitive Landscape to 2026

Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. T1D can develop at any age, but is frequently observed in children and adolescents.

This report provides an assessment of the pipeline, clinical, and commercial landscape of T1D. Overall, GlobalData expects new insulins and SGLT inhibitor approvals to drive T1D market growth during the next decade.

Scope

GlobalData’s Type 1 Diabetes (T1D): Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:

• Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type

• Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

• Commercial Assessment—leading marketed products, current and future players

• Competitive Landscape Analysis—key market events (2016–2026)

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global Type 1 Diabetes (T1D) market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Type 1 Diabetes (T1D) market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

Boehringer Ingelheim

Eli Lilly

AstraZeneca

Sanofi

Novo Nordisk

Lexicon

Astellas

Table of Contents

Table of Contents (PowerPoint Deck)

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Disease Overview & Epidemiology

4 Pipeline Assessment

4.1 Pipeline Overview

4.2 Pipeline Breakdown by Region/Country

4.3 Pipeline Breakdown by Molecule Type and Target

4.4 Drug Review Designations

4.5 Products in Clinical Development

5 Clinical Trial Assessment

5.1 Clinical Trials Overview

5.2 Top Sponors of Clinical Trials in T1D

5.3 Trial Breakdown by Region

5.4 Therapy Area Perspective

5.5 Enrollment Analytics

6 Commercial Assessment

6.1 Leading Marketed Products

6.2 Current & Future Players

7 Competitive Landscape Analysis (2016–2026)

7.1 Events and Segmentation Overview

7.2 US

7.3 5EU

7.4 Japan and China

8 Appendix

8.1 Sources

8.2 Methodology

8.3 Key Events Included in the Analysis

8.4 About the Authors

8.5 About GlobalData

8.6 Disclaimer

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports